New triple therapy aims to boost immune attack on aggressive breast cancer
Disease control
Recruiting now
This study tests whether adding a drug that blocks a certain immune cell (CSF-1R inhibitor) and radiation to standard immunotherapy (pembrolizumab) can help the body fight high-risk triple-negative breast cancer more effectively. About 35 women with this aggressive cancer will re…
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC